Mutual of America Capital Management LLC Has $6.85 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Mutual of America Capital Management LLC grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,324 shares of the company’s stock after purchasing an additional 3,135 shares during the quarter. Mutual of America Capital Management LLC owned about 0.13% of Krystal Biotech worth $6,854,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its holdings in Krystal Biotech by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after acquiring an additional 231,255 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Krystal Biotech by 1.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Hood River Capital Management LLC boosted its position in Krystal Biotech by 8.1% during the first quarter. Hood River Capital Management LLC now owns 495,586 shares of the company’s stock worth $88,180,000 after purchasing an additional 37,073 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in Krystal Biotech by 23.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock worth $28,292,000 after purchasing an additional 43,709 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $184.48 on Friday. Krystal Biotech, Inc. has a twelve month low of $93.95 and a twelve month high of $219.34. The stock has a market cap of $5.27 billion, a PE ratio of 98.65 and a beta of 0.82. The firm has a 50-day simple moving average of $195.52 and a 200 day simple moving average of $179.21.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.25) EPS. Research analysts forecast that Krystal Biotech, Inc. will post 3.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on KRYS. Chardan Capital boosted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. HC Wainwright upped their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Finally, Citigroup restated a “neutral” rating and set a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $196.75.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).